Recent clinical trials have reignited the interest in simple anti-inflammatory drugs like aspirin for controlling the inflammation associated with cancer. The results suggest that these drugs reduced the risk of relapse as well as cancer formation across many types of cancer. However, aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) can have severe gastrointestinal and cardiovascular side effects, so researchers have been looking for other ways that cancer and inflammation intersect in the hope of finding a better target for therapy.
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?